No-reflow: again prevention is better than treatment.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  European Heart Journal

• Publication date

  2010-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/eurheartj/ehq299PMID 20837571
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Postconditioning during primary percutaneous coronary intervention: a review and meta-analysis.

  2010cited by this paper
• Effect of chronic Aspirin therapy on angiographic thrombotic burden in patients admitted for a first ST-elevation myocardial infarction.

  2010cited by this paper
• Intracoronary Eptifibatide Bolus Administration During Percutaneous Coronary Revascularization for Acute Coronary Syndromes With Evaluation of Platelet Glycoprotein IIb/IIIa Receptor Occupancy and Platelet Function: The Intracoronary Eptifibatide (ICE) Trial

  2010cited by this paper
• Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.

  2010influential reference
• Cardioprotective Effects of Ischemic Postconditioning in Patients Treated With Primary Percutaneous Coronary Intervention, Evaluated by Magnetic Resonance

  2010cited by this paper
• PROTECTIVE EFFECT OF ISCHEMIC PRECONDITIONING ON ISCHEMIA/REPERFUSION INDUCED MICROVASCULAR OBSTRUCTION DETERMINED BY ON-LINE MEASUREMENTS OF CORONARY PRESSURE AND BLOOD FLOW IN PIGS

  2010cited by this paper
• Chronic nitrate therapy is associated with different presentation and evolution of acute coronary syndromes: insights from 52,693 patients in the Global Registry of Acute Coronary Events.

  2010cited by this paper
• Remote ischemic preconditioning decreases adhesion and selectively modifies functional responses of human neutrophils.

  2010cited by this paper
• Cardioprotective role of remote ischemic periconditioning in primary percutaneous coronary intervention: enhancement by opioid action.

  2010cited by this paper
• Clinical cardioprotection and the value of conditioning responses.

  2009cited by this paper
• Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial.

  2009cited by this paper
• Preconditioning and postconditioning: underlying mechanisms and clinical application.

  2009cited by this paper
• Myocardial no-reflow in humans.

  2009influential reference
• Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial.

  2009influential reference
• Translation of remote ischaemic preconditioning into clinical practice.

  2009cited by this paper
• Protective effect of ischaemic preconditioning on ischaemia/reper-fusion-induced microvascular obstruction determined by online measurements of coronary pressure and blood flow in pigs

  2009cited by this paper
• Adenosine receptors and inflammation.

  2009cited by this paper
• Effect of cyclosporine on reperfusion injury in acute myocardial infarction.

  2008cited by this paper
• Thrombus aspiration during primary percutaneous coronary intervention.

  2008cited by this paper
• Thrombus aspiration during primary percutaneous coronary intervention.

  2008cited by this paper
• Intracoronary Compared With Intravenous Bolus Abciximab Application in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: The Randomized Leipzig Immediate Percutaneous Coronary Intervention Abciximab IV Versus IC in ST-Elevation Myocardial Infarct

  2008cited by this paper
• Ethanol abolishes ischemic preconditioning in humans.

  2008cited by this paper
• Coronary no‐reflow phenomenon: From the experimental laboratory to the cardiac catheterization laboratory

  2008cited by this paper
• Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials

  2008influential reference
• High dose adenosine for suboptimal myocardial reperfusion after primary PCI: A randomized placebo‐controlled pilot study

  2007cited by this paper
• Myocardial reperfusion injury.

  2007cited by this paper
• Frequency of slow coronary flow following successful stent implantation and effect of Nitroprusside.

  2007cited by this paper
• No-Reflow Phenomenon After Acute Myocardial Infarction Is Associated With Reduced Clot Permeability and Susceptibility to Lysis

  2007cited by this paper
• Effect of Distal Embolization on Myocardial Perfusion Reserve After Percutaneous Coronary Intervention: A Quantitative Magnetic Resonance Perfusion Study

  2007cited by this paper
• Rationale for intracoronary administration of abciximab

  2007cited by this paper
• Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up.

  2007cited by this paper
• Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial.

  2007cited by this paper
• Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials.

  2007cited by this paper
• Pretreatment with fosinopril or valsartan reduces myocardial no-reflow after acute myocardial infarction and reperfusion

  2006cited by this paper
• Caffeine prevents protection in two human models of ischemic preconditioning.

  2006cited by this paper
• Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction.

  2006influential reference
• Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in congestive heart failure.

  2006cited by this paper
• Coronary microembolization

  2006cited by this paper
• Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial.

  2006cited by this paper
• The no-reflow phenomenon: A basic mechanism of myocardial ischemia and reperfusion

  2006cited by this paper
• The acute reperfusion management of STEMI in patients with impaired glucose tolerance and type 2 diabetes

  2005cited by this paper
• Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine.

  2005cited by this paper
• Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction.

  2005cited by this paper
• A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II).

  2005cited by this paper
• Impact of a Single Intravenous Administration of Nicorandil Before Reperfusion in Patients With ST-Segment–Elevation Myocardial Infarction

  2005cited by this paper
• Coronary microembolization*1

  2004cited by this paper
• Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: role of inhibitory effect on reactive oxygen species formation.

  2004cited by this paper
• Myocardial Reperfusion Injury

  2004influential reference
• Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways.

  2004cited by this paper
• Transient limb ischemia induces remote ischemic preconditioning in vivo.

  2003cited by this paper
• Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction.

  2003cited by this paper
• Preconditioning the myocardium: from cellular physiology to clinical cardiology.

  2003influential reference
• Temporal evolution and functional outcome of no reflow: sustained and spontaneously reversible patterns following successful coronary recanalisation

  2003cited by this paper
• Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.

  2003cited by this paper
• Intracoronary verapamil for reversal of no‐reflow during coronary angioplasty for acute myocardial infarction

  2002cited by this paper
• Transient Limb Ischemia Induces Remote Ischemic Preconditioning In Vivo

  2002cited by this paper
• Combination Therapy With Abciximab Reduces Angiographically Evident Thrombus in Acute Myocardial Infarction: A TIMI 14 Substudy

  2001cited by this paper
• Neutrophils are primary source of O2 radicals during reperfusion after prolonged myocardial ischemia.

  2001cited by this paper
• Coronary microembolization.

  2001cited by this paper
• The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial.

  2001cited by this paper
• Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction.

  2000cited by this paper
• Inhibition of the Sodium-Hydrogen Exchanger With Cariporide to Prevent Myocardial Infarction in High-Risk Ischemic Situations: Main Results of the GUARDIAN Trial

  2000cited by this paper
• The myocardial Na(+)-H(+) exchange: structure, regulation, and its role in heart disease.

  1999cited by this paper
• Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction.

  1999cited by this paper
• Myocardial Infarction Adenosine as an Adjunct to Thrombolytic Therapy for Acute Myocardial Infarction

  1999cited by this paper
• Magnitude and time course of microvascular obstruction and tissue injury after acute myocardial infarction.

  1998cited by this paper
• Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction.

  1997cited by this paper
• Ischemic preconditioning attenuates capillary no-reflow induced by prolonged ischemia and reperfusion.

  1995cited by this paper
• Adenosine activates A2 receptors to inhibit neutrophil adhesion and injury to isolated cardiac myocytes.

  1995cited by this paper
• Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year.

  1995cited by this paper
• Ischemic Preconditioning During Coronary Angioplast Is Prevented by Glibenclamide, a Selective ATP‐Sensitive K+ Channel Blocker

  1994cited by this paper
• Lack of Myocardial Perfusion Immediately After Successful Thrombolysis: A Predictor of Poor Recovery of Left Ventricular Function in Anterior Myocardial Infarction

  1992cited by this paper
• Progressive impairment of regional myocardial perfusion after initial restoration of postischemic blood flow.

  1989cited by this paper
• The effect of acute hypercholesterolemia on myocardial infarct size and the no-reflow phenomenon during coronary occlusion-reperfusion.

  1987cited by this paper

• COMPARISON OF DEFLATED BALLOON-FACILITATED DIRECT STENTING AND CONVENTIONAL BALLOON PRE-DILATATION IN PRIMARY PERCUTANEOUS CORONARY INTERVENTION FOR ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION

  2025cites this paper
• Derived neutrophil-to-lymphocyte ratio as a predictor of no-reflow in ST-elevation myocardial infarction.

  2025cites this paper
• Serum IL-1β as a Novel Predictor of No-Reflow in STEMI Patients Undergoing Primary PCI

  2025cites this paper
• Impact of intracoronary adenosine on the no-reflow phenomenon: A randomized, triple-blind, placebo-controlled clinical trial

  2025cites this paper
• Effect of empagliflozin on reducing the no-reflow phenomenon in patients with ST-elevation myocardial infarction: rationale and design of the EMPA-PCI trial

  2025cites this paper
• LncRNA EBLN3P inhibits myocardial inflammation and apoptosis after acute myocardial infarction via targeting miR-675-3p

  2025cites this paper
• Myocardial contrast echocardiography predicts major adverse cardiovascular and cerebrovascular events in the population after percutaneous coronary intervention—a systematic review and meta-analysis

  2025cites this paper
• Role of Endothelin-1 on Myocardial Ischemia-Reperfusion Injury: A Comprehensive Review

  2025cites this paper
• Short-term effects of upstream high bolus dose of tirofiban in patients with ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

  2025cites this paper
• Impact on slow-flow/no-reflow of intravascular ultrasound-guided primary percutaneous coronary intervention in ST-elevation myocardial infarction

  2025cites this paper
• Vitamin C as Scavenger of Reactive Oxygen Species during Healing after Myocardial Infarction

  2024cites this paper
• Prevalencia e implicaciones pronósticas del fenómeno de no reflujo en pacientes sometidos a intervencionismo coronario percutáneo primario en un centro universitario de un país de ingresos medios

  2024cites this paper
• Targeting Gαi2 in neutrophils protects from myocardial ischemia reperfusion injury

  2024cites this paper
• The non-HDL-C/HDL-C ratio is a strong and independent predictor of the no-reflow phenomenon in patients with ST-elevation myocardial infarction

  2024cites this paper
• Incidencia de eventos cardiovasculares mayores intrahospitalarios en pacientes sometidos a tromboaspiración mecánica más IIb/IIIa contra solo inhibidores de la glucoproteína IIb/IIIa en infarto agudo al miocardio con elevación del segmento ST

  2024cites this paper
• A Machine Learning Model for the Prediction of No-Reflow Phenomenon in Acute Myocardial Infarction Using the CALLY Index

  2024cites this paper
• Predicting the no-reflow phenomenon in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a systematic review of clinical prediction models

  2024cites this paper
• Differential roles of eosinophils in cardiovascular disease

  2024cites this paper
• Clinical variables associated with no-reflow after percutaneous coronary intervention in ST-segment elevation myocardial infarction: Secondary analysis of PERSTEMI I and II registries

  2023cites this paper
• THE ROLE OF STATINS IN REDUCING THE RISK OF NO-SLOW-REFLOW BY CORONARY REVASCULARISATION

  2023cites this paper
• The Relationship Between TIMI Flow and MAPH Score in Patients Undergoing Primary Percutaneous Coronary Intervention for STEMI.

  2023cites this paper
• No-reflow after primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: an angiographic core laboratory analysis of the TOTAL Trial.

  2023cites this paper
• Association of Epicardial Adipose Tissue With Left Ventricular Strain and MR Myocardial Perfusion in Patients With Known Coronary Artery Disease

  2023cites this paper
• Risk assessment score of no-reflow phenomenon in predicting myocardial perfusion disorders by contrast echocardiography in ST-segment elevation myocardial infarction patients after endovascular revascularization

  2022cites this paper
• Variables clínicas asociadas a no reflujo tras la intervención coronaria percutánea en el infarto de miocardio con elevación del segmento ST: análisis secundario del estudio PERSTEMI I y II

  2022influential citation
• The Association of Serum Uric Acid/Albumin Ratio with No-Reflow in Patients with ST Elevation Myocardial Infarction

  2022influential citation
• Intracoronary Administration of Drugs in Clinical Practice

  2022cites this paper
• Adenosine as adjunctive therapy in acute coronary syndrome: a meta-analysis of randomized controlled trials.

  2022cites this paper
• The Association Between No-Reflow and Serum Uric Acid/Albumin Ratio in Patients With Acute Myocardial Infarction Without ST Elevation

  2022cites this paper
• The cardiac wound healing response to myocardial infarction

  2022cites this paper
• “No-Reflow” Phenomenon: A Contemporary Review

  2022cites this paper
• The predictive value of eosinophil levels on no-reflow in patients with STEMI following PCI: a retrospective cohort study

  2022cites this paper
• Preprocedural Colchicine in Patients With Acute ST-elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: A Randomized Controlled Trial (PodCAST-PCI)

  2022cites this paper
• [The no-Reflow Phenomenon During Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction due to Massive Coronary Thrombosis. Pathogenesis and Predictors of no-Reflow].

  2021cites this paper
• Mitochondrial Biomarkers in Patients with ST-Elevation Myocardial Infarction and Their Potential Prognostic Implications: A Prospective Observational Study

  2021cites this paper
• Microvascular Obstructions Measured by Cardiac Magnetic Resonance, and their Role as a Predictor of Outcomes in Acute Myocardial Infarction

  2021cites this paper
• Role of Combination therapy on no-reflow after primarypercutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction

  2021cites this paper
• Coronary Microvascular Adaptations Distal to Epicardial Artery Stenosis.

  2021cites this paper
• Mechanobiology of Microvascular Function and Structure in Health and Disease: Focus on the Coronary Circulation

  2021cites this paper
• Refractory No-Reflow Phenomenon: Do We Need a New Player?

  2021cites this paper
• No-Reflow phenomenon in the perspective of endovascular neurosurgery

  2021cites this paper
• For Prediction of “No-Reflow,” How Precise is PRECISE-DAPT?

  2021cites this paper
• TAX1BP1 protects against myocardial infarction-associated cardiac anomalies through inhibition of inflammasomes in a RNF34/MAVS/NLRP3-dependent manner.

  2021cites this paper
• The impact of lesion complexity on no-reflow phenomenon and predictors of reversibility in patients treated with primary percutaneous intervention

  2020cites this paper
• “No-reflow”: update su diagnosi, fisiopatologia e strategie terapeutiche

  2020cites this paper
• Two-Stage Revascularization in Patients with Acute Myocardial Infarction and Massive Coronary Thrombosis

  2019cites this paper
• Is Atherothromboaspiration a Possible Solution for the Prevention of No-Reflow Phenomenon in Acute Coronary Syndromes? Single Centre Experience and Review of the Literature.

  2019cites this paper
• Application of virtual histological intravascular ultrasound in plaque composition assessment of saphenous vein graft diseases

  2019cites this paper
• Clinical and procedural predictors of suboptimal myocardial reperfusion in primary percutaneous coronary intervention

  2019cites this paper
• Двухэтапная реваскуляризация у пациентов с острым инфарктом миокарда и массивным тромбозом коронарной артерии

  2019cites this paper
• Effects of Nicorandil on All-Cause Mortality and Cardiac Events in CAD Patients Receiving PCI.

  2019cites this paper
• Impact of intracoronary contrast injection pressure on reperfusion during primary percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: A prospective randomized pilot study

  2019cites this paper
• Microcirculation in Cardiovascular Diseases.

  2019cites this paper
• Usefulness of intracoronary administration of fasudil, a selective Rho-kinase inhibitor, for PCI-related refractory myocardial ischemia.

  2019cites this paper
• Role of Coronary Microcirculation in No-Reflow Phenomenon in Myocardial Infarction with ST Segment Elevation

  2019cites this paper
• Prediction of Major Adverse Cardiovascular Events and Slow/No-Reflow by Virtual Histology Imaging After Percutaneous Interventions on Saphenous Vein Grafts

  2019cites this paper
• Assessing and managing coronary microcirculation dysfunction in acute ST-segment elevation myocardial infarction

  2018cites this paper
• Editor’s Choice- Reperfusion cardiac arrhythmias and their relation to reperfusion-induced cell death

  2018cites this paper
• Advances in Coronary No-Reflow Phenomenon—a Contemporary Review

  2018cites this paper
• Reduction of No Reflow with a Loading Dose of Atorvastatin before Primary Angioplasty in Patients with Acute ST Myocardial Infarction.

  2018cites this paper
• Hyperaemic microvascular resistance predicts clinical outcome and microvascular injury after myocardial infarction

  2017cites this paper
• Feasibility of Extracorporeal Shock Wave Myocardial Revascularization Therapy for Post-Acute Myocardial Infarction Patients and Refractory Angina Pectoris Patients.

  2017cites this paper
• MIKROVASKULINĖ DISFUNKCIJA KARDIOLOGIJOS PRAKTIKOJE

  2017cites this paper
• Prognostic value of plasma DPP4 activity in ST-elevation myocardial infarction

  2017cites this paper
• Current perspectives in coronary microvascular dysfunction

  2017cites this paper
• Factors associated with the no-reflow phenomenon following percutaneous intervention of saphenous vein coronary bypass grafts

  2017cites this paper
• Fenómeno de No Reflow en síndrome coronario agudo con elevación del segmento ST

  2016cites this paper
• Coronary microvascular obstruction in acute myocardial infarction.

  2016cites this paper
• Thrombus aspiration in acute myocardial infarction

  2016cites this paper
• Zjawisko no-reflow — patogeneza, rozpoznawanie, postępowanie

  2016cites this paper
• The Predictors of No-Reflow Phenomenon after Primary Angioplasty for Acute Myocardial Infarction

  2016cites this paper
• Coronary microvascular dysfunction

  2015cites this paper
• Short-term outcomes in patients with acute coronary syndrome treated with direct bioresorbable scaffold deployment.

  2015cites this paper
• Infusión intracoronaria de tioflavina-S para el estudio de la obstrucción microvascular en un modelo de infarto de miocardio

  2015cites this paper
• Effects of different routes of tirofiban injection on the left ventricular function and prognosis of patients with myocardial infarction treated with percutaneous coronary intervention.

  2015cites this paper
• No-reflow phenomenon during PCI in acute myocardial infarction

  2015cites this paper
• Intracoronary Infusion of Thioflavin-S to Study Microvascular Obstruction in a Model of Myocardial Infarction.

  2015cites this paper
• The no-reflow phenomenon: State of the art.

  2015cites this paper
• Novel insights into an "old" phenomenon: the no reflow.

  2015cites this paper
• Angiopoietin-like 4 serum levels on admission for acute myocardial infarction are associated with no-reflow.

  2015cites this paper
• Coronary microvascular dysfunction: an update.

  2014cites this paper
• Acute Coronary

  2014influential citation
• The value of plasma D-dimer level on admission in predicting no-reflow after primary percutaneous coronary intervention and long-term prognosis in patients with acute ST segment elevation myocardial infarction

  2014cites this paper
• MGuard Embolic Protection Stent - The Importance of Thrombus Management in ST-elevation Myocardial Infarction Primary Percutaneous Coronary Intervention: Proceedings of STEMI symposium at EuroPCR on 20-23rd May 2014 in Paris.

  2014cites this paper
• Extracorporeal Life Support in Adults With Hemodynamic Collapse from Fulminant Cardiomyopathies: The Chance of Bridging to Recovery

  2014cites this paper
• No-Reflow Phenomenon

  2014influential citation
• The role of MGuard stent in primary coronary angioplasty.

  2014cites this paper
• Non-Antithrombotic Medical Options in ACS: Old Agents and New Lines on the Horizon

  2014cites this paper
• Acute Coronary Syndromes Compendium

  2014influential citation
• Development of a novel adenosine-eluting guidewire (Adenowire) for coronary vasodilation during percutaneous coronary intervention.

  2014cites this paper
• Coronary microvascular dysfunction in patients without myocardial diseases and obstructive atherosclerosis

  2014cites this paper
• Nonantithrombotic Medical Options in Acute Coronary Syndromes: Old Agents and New Lines on the Horizon

  2014influential citation
• Zjawiska slow-flow, no-reflow, dystalna embolizacja — klasyfikacja, rokowanie i możliwości zapobiegania

  2013cites this paper
• Beyond Culprit Vessel Recanalization in Myocardial Infarction with ST-Segment Elevation

  2013cites this paper
• Patients with microvascular obstruction after primary percutaneous coronary intervention show a gp91phox (NOX2) mediated persistent oxidative stress after reperfusion

  2013cites this paper
• Myocardial 'no-reflow' prevention.

  2013cites this paper
• Myocardial no-reflow treatment.

  2013cites this paper
• Persistent enhanced platelet activation in patients with acute myocardial infarction and coronary microvascular obstruction: clinical implications

  2013cites this paper
• Microvascular obstruction after primary percutaneous coronary intervention: pathogenesis, diagnosis and prognostic significance.

  2013cites this paper
• Development and Validation of a Clinical Risk Score Predicting the No-Reflow Phenomenon in Patients Treated with Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction

  2013cites this paper